VC and Investment
Biotechnology
US clinical-stage biotech Apogee Therapeutics today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart. 27 May 2026
Today's issue
Refine search
Biotechnology
US biotech Regenxbio on Friday announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions. 20 July 2026
Biotechnology
USA-based BlossomHill Therapeutics has become the sixth biotech to line up for a stock market debut in July, filing to go public as investor enthusiasm for new drug listings shows little sign of cooling. The San Diego oncology specialist has applied to list on the Nasdaq Global Select Market under the ticker BLSM. 20 July 2026
Biotechnology
USA-based biotech Latigo Biotherapeutics has thrown open its books to public investors, using a Friday filing with the Securities and Exchange Commission to reveal mid-stage results for its lead non-opioid pain candidate LTG-001 while laying out plans to raise fresh capital through a stock market debut. 20 July 2026
Biotechnology
UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion ($2.84 billion), including a record £2.05 billion in venture capital, according to new figures from the BioIndustry Association (BIA). 20 July 2026
Biotechnology
IPOs are back. The first six months of 2026 have seen a some of the biggest stock
market debuts in biopharma history. With IPOs regularly topping the $200m mark,
the amount of money raised in the first half of the year has eclipsed what the entire
sector managed in the whole of 2025. 17 July 2026
Biotechnology
US biotech Jasper Therapeutics has completed its all-stock acquisition of complement-focused Kira Pharmaceuticals, creating a combined immunology company with a broader biologics pipeline for immune-mediated diseases. 17 July 2026
Biotechnology
Australian radiopharmaceutical company AdvanCell has closed an oversubscribed and upsized $315 million Series D financing to advance its targeted alpha therapy pipeline and expand its manufacturing network. 15 July 2026
Pharmaceutical
US AI drug discovery firm Chai Discovery has raised $400 million in a Series C financing, valuing the San Francisco-based company at $3.8 billion as it looks to expand use of its molecular design platform across the pharma industry. 15 July 2026
Biotechnology
Cambridge, USA-based biotech Spero Therapeutics on Tuesday announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR. 15 July 2026
Biotechnology
US commercial-stage biotech Mighty Therapeutics today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. 14 July 2026
Pharmaceutical
Clinical-stage biopharmaceutical company Draig Therapeutics has closed an oversubscribed $65 million Series B financing to support development of its neuropsychiatry pipeline, led by the Phase II major depressive disorder candidate DT-101. 14 July 2026
Pharmaceutical
UK headquartered ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights in the respiratory clinical development space, has completed a major corporate repositioning and reorganization. The move marks the next stage of the company's development. 14 July 2026
Biotechnology
US immune-oncology drug developer Agenus’ stock surged more than 125% to $7.57 in morning trading on Monday, after it announced a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. 14 July 2026
Biotechnology
The biotech infrastructure sector has changed significantly since the biotechnology funding peak of 2021. 14 July 2026
Biotechnology
Barcelona, Spain-based CriteriaCaixa, the holding company that manages the business assets of ‘la Caixa’ Banking Foundation, today announces a reboot of its start-up investment business to facilitate the growth of science and technology-based high-potential emerging companies. 13 July 2026
Pharmaceutical
Sweden-based KDventures AB today announced that its portfolio company PharmNovo has completed a capital raise of approximately 39 million kronor ($4.1 million), with participation from external investors. 10 July 2026
Biotechnology
China’s MindRank AI has completed a $52 million Series B financing round, with investors including leading renminbi and US dollar funds. Kaiwu Capital served as the exclusive financial advisor. 9 July 2026
Biotechnology
UK biotech company Alchemab Therapeutics has secured a £25 million ($34 million) Series A extension from the British Business Bank, in what the Bank says is its largest direct investment in a life sciences company. 9 July 2026
Biotechnology
French genetic medicines company Cyllene Therapeutics has raised 33 million euros ($38 million) in series C financing to support development of its lead neuro-urology candidate EG110A, as the company rebrands from EG 427 and moves closer to late-stage clinical testing. 8 July 2026
Biotechnology
Biopharma coverage often focuses on two parts of the industry: the largest global drugmakers and the smallest venture-backed biotech companies. Between them sits a broad group of mid-sized regional companies that play an important role in how medicines are developed, manufactured, licensed and commercialized. 7 July 2026
Biotechnology
US biotech Regenxbio on Friday announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions. 20 July 2026
Biotechnology
USA-based BlossomHill Therapeutics has become the sixth biotech to line up for a stock market debut in July, filing to go public as investor enthusiasm for new drug listings shows little sign of cooling. The San Diego oncology specialist has applied to list on the Nasdaq Global Select Market under the ticker BLSM. 20 July 2026
Biotechnology
USA-based biotech Latigo Biotherapeutics has thrown open its books to public investors, using a Friday filing with the Securities and Exchange Commission to reveal mid-stage results for its lead non-opioid pain candidate LTG-001 while laying out plans to raise fresh capital through a stock market debut. 20 July 2026
Biotechnology
UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion ($2.84 billion), including a record £2.05 billion in venture capital, according to new figures from the BioIndustry Association (BIA). 20 July 2026
Biotechnology
IPOs are back. The first six months of 2026 have seen a some of the biggest stock
market debuts in biopharma history. With IPOs regularly topping the $200m mark,
the amount of money raised in the first half of the year has eclipsed what the entire
sector managed in the whole of 2025. 17 July 2026
Biotechnology
US biotech Jasper Therapeutics has completed its all-stock acquisition of complement-focused Kira Pharmaceuticals, creating a combined immunology company with a broader biologics pipeline for immune-mediated diseases. 17 July 2026
Biotechnology
Australian radiopharmaceutical company AdvanCell has closed an oversubscribed and upsized $315 million Series D financing to advance its targeted alpha therapy pipeline and expand its manufacturing network. 15 July 2026
Pharmaceutical
US AI drug discovery firm Chai Discovery has raised $400 million in a Series C financing, valuing the San Francisco-based company at $3.8 billion as it looks to expand use of its molecular design platform across the pharma industry. 15 July 2026
Biotechnology
Cambridge, USA-based biotech Spero Therapeutics on Tuesday announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR. 15 July 2026
Biotechnology
US commercial-stage biotech Mighty Therapeutics today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. 14 July 2026
Pharmaceutical
Clinical-stage biopharmaceutical company Draig Therapeutics has closed an oversubscribed $65 million Series B financing to support development of its neuropsychiatry pipeline, led by the Phase II major depressive disorder candidate DT-101. 14 July 2026
Pharmaceutical
UK headquartered ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights in the respiratory clinical development space, has completed a major corporate repositioning and reorganization. The move marks the next stage of the company's development. 14 July 2026
Biotechnology
US immune-oncology drug developer Agenus’ stock surged more than 125% to $7.57 in morning trading on Monday, after it announced a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. 14 July 2026
Biotechnology
The biotech infrastructure sector has changed significantly since the biotechnology funding peak of 2021. 14 July 2026
Biotechnology
Barcelona, Spain-based CriteriaCaixa, the holding company that manages the business assets of ‘la Caixa’ Banking Foundation, today announces a reboot of its start-up investment business to facilitate the growth of science and technology-based high-potential emerging companies. 13 July 2026
Pharmaceutical
Sweden-based KDventures AB today announced that its portfolio company PharmNovo has completed a capital raise of approximately 39 million kronor ($4.1 million), with participation from external investors. 10 July 2026
Biotechnology
China’s MindRank AI has completed a $52 million Series B financing round, with investors including leading renminbi and US dollar funds. Kaiwu Capital served as the exclusive financial advisor. 9 July 2026
Biotechnology
UK biotech company Alchemab Therapeutics has secured a £25 million ($34 million) Series A extension from the British Business Bank, in what the Bank says is its largest direct investment in a life sciences company. 9 July 2026
Biotechnology
French genetic medicines company Cyllene Therapeutics has raised 33 million euros ($38 million) in series C financing to support development of its lead neuro-urology candidate EG110A, as the company rebrands from EG 427 and moves closer to late-stage clinical testing. 8 July 2026
Biotechnology
Biopharma coverage often focuses on two parts of the industry: the largest global drugmakers and the smallest venture-backed biotech companies. Between them sits a broad group of mid-sized regional companies that play an important role in how medicines are developed, manufactured, licensed and commercialized. 7 July 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze